Docetaxel Injection

It is an anti-tumor drug belonging to the taxane class of compounds. The mechanism of action of this product is to enhance tubulin polymerization and inhibit microtubule depolymerization, leading to the formation of stable non-functional microtubule bundles, thereby destroying the mitosis of tumor cells. The intracellular concentration of this product is 3 times higher than that of paclitaxel, and it has a longer intracellular retention time, which is an important reason why this product has greater anti-tumor activity than paclitaxel in in vitro tests. In in vivo tests, it is effective against colon cancer, breast cancer, lung cancer, and ovarian tumor transplants in mice. This product does not produce cross-resistance to cell lines resistant to cisplatin, etoposide, 5Fu, or paclitaxel.

The main ingredient of this product is docetaxel.

This product is a light yellow to yellow clear viscous liquid

1. Docetaxel is suitable for the treatment of advanced or metastatic breast cancer after failure of previous chemotherapy. Unless it is clinically contraindicated, previous treatment should include anthracycline anticancer drugs. 2. Docetaxel is suitable for the treatment of advanced or metastatic non-small cell lung cancer after failure of chemotherapy based on cisplatin.

Docetaxel can only be used for intravenous infusion. All patients must take oral glucocorticoids, such as dexamethasone, before receiving docetaxel treatment, one day before docetaxel infusion. 16 mg per day, for at least 3 days, to prevent allergic reactions and fluid retention. Before use, inhale all the solvent corresponding to docetaxel into the corresponding solution, shake gently to mix evenly, leave the mixed bottle at room temperature for 5 minutes, then check whether the solution is uniform and clear, and according to the calculated amount of medicine used by the patient, inhale the mixture with a syringe, inject it into the injection bottle or injection bag of 5% glucose injection or 0.9% sodium chloride injection, shake gently, mix evenly, and the final concentration shall not exceed 0.9 mg/ml. The recommended dose of docetaxel is 75 mg/m2 drip for one hour, once every three weeks

1. Bone marrow suppression: Neutropenia is the most common side effect and is usually severe (less than 500/mm3). It is reversible and does not accumulate. 2. Allergic reactions: Severe allergic reactions may occur in some cases, characterized by hypotension and bronchospasm, requiring interruption of treatment. Patients can return to normal after stopping the infusion and immediate treatment. Mild allergic reactions may also occur in some cases. Such as flushing, erythema with or without itching, chest tightness, back pain, dyspnea, drug fever or chills. 3. Skin reactions often manifest as erythema, mainly seen on the hands and feet, and may also occur in local rashes on the arms, face and chest, sometimes accompanied by itching. The rash may usually occur within a week after the infusion of docetaxel, but may recover before the next infusion. Severe symptoms such as peeling after the rash rarely occur. Nail lesions may occur. Characterized by pigmentation or lightening, sometimes pain and nail loss. 4. Fluid retention includes edema. There are also reports of rare cases of pleural effusion, ascites, pericardial effusion, increased capillary permeability and weight gain. After 4 cycles of treatment or a cumulative dose of 400 mg/m2, fluid retention occurs in the lower limbs and may develop into systemic edema, with a weight gain of 3 kg or more. Fluid retention gradually disappears after stopping docetaxel treatment. In order to reduce fluid retention, patients should be given prophylactic corticosteroids. 5. Gastrointestinal reactions such as nausea, vomiting or diarrhea may occur. 6. Neurotoxicity has been reported in clinical trials. 7. Cardiovascular side effects such as hypotension, sinus tachycardia, palpitations, pulmonary edema and hypertension may occur. 8. Other side effects include: hair loss, weakness, mucositis, arthralgia and myalgia, hypotension and injection site reactions. 9. Patients with normal liver function also experienced elevated aminotransferases and bilirubin during treatment, and their relationship with docetaxel is not yet clear.

1. Patients with a history of severe allergic reaction to docetaxel or Tween-80. 2. Patients with a white blood cell count less than 1500/mm3. 3. Patients with severe liver damage.

In vitro studies have shown that CYP3A4 inhibitors may interfere with the metabolism of this product, so extreme caution should be exercised when it is used simultaneously with such drugs (such as ketoconazole, erythromycin, cyclosporine, etc.).

Keep in a dark and airtight container at 2-8℃.

0.5 ml: 20 mg